pharmaphorum4d
Lynparza set for narrow prostate cancer use after FDA vote
AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...
pharmaphorum2d
NICE says no to AZ’s Lynparza for prostate cancer
NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.
Pharm Exec26d
Follow-Up Results from OlympiA Trial Highlight 28% Mortality Benefit with Lynparza in gBRCAm Breast Cancer
PE: The six-year follow-up from the OlympiA trial showed a 28% reduction in the risk of death with Lynparza. How does this result compare to other treatments available for gBRCAm HER2-negative ...